HC Wainwright Reaffirms Buy Rating for Immuron Limited – American Depositary Shares (IMRN)
Immuron Limited – American Depositary Shares (NASDAQ:IMRN)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a research report issued to clients and investors on Friday. They currently have a $20.00 price target on the stock. HC Wainwright’s price objective suggests a potential upside of 76.21% from the stock’s current price.
Immuron Limited – American Depositary Shares (IMRN) opened at $11.35 on Friday. Immuron Limited – American Depositary Shares has a 52 week low of $4.47 and a 52 week high of $16.70.
ILLEGAL ACTIVITY NOTICE: “HC Wainwright Reaffirms Buy Rating for Immuron Limited – American Depositary Shares (IMRN)” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.thecerbatgem.com/2018/03/11/hc-wainwright-reaffirms-buy-rating-for-immuron-limited-american-depositary-shares-imrn.html.
About Immuron Limited – American Depositary Shares
Immuron Limited, a microbiome company, focuses on developing and commercializing oral immunotherapeutics for the treatment of various gut medicated diseases in Australia and internationally. The company operates through Research and Development, and HyperImmune Products segments. It has a technology platform that enables a shorter development therapeutic cycle.
Receive News & Ratings for Immuron Limited - American Depositary Shares Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immuron Limited - American Depositary Shares and related companies with MarketBeat.com's FREE daily email newsletter.